TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
Patients with inoperable endometrial cancer have limited treatment options. PD-L1 expression
is common in endometrial cancers and RT induces tumor and systemic changes that induce the
immune system. The purpose of this trial is to evaluate anti-PD-1/PD-L1 axis therapy in
conjunction of standard of care RT for patients with inoperable endometrial cancer in order
to establish the safety and efficacy of inducing an anti-tumor immune response.